Heron Therapeutics Inc
Uždarymo kaina
SektoriusSveikatos priežiūra
0.32 -3.03
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
0.31
Max
0.34
Pajamos | 2.6M -5.5M |
|---|---|
Pardavimai | 3M 38M |
Pelnas, tenkantis vienai akcijai | -0.03 |
Pelno marža | -14.573 |
Darbuotojai | 128 |
EBITDA | 2.1M -5.5M |
Kitas uždarbis | 2026-11-03 |
|---|
Rinkos kapitalizacija | -36M 61M |
|---|---|
Ankstesnė atidarymo kaina | 3.35 |
Ankstesnė uždarymo kaina | 0.32 |
Naujienos nuotaikos
By Acuity
46%
54%
148 / 340 reitingas Healthcare
Heron Therapeutics Inc Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Susijusios naujienos
Akcijų palyginimas
Kainos pokytis
Heron Therapeutics Inc Prognozė
Rinkos nuotaikos
By Acuity
148 / 340 reitingas Sveikatos priežiūra
Naujienos nuotaikos
Bulių rinkos įrodymas
Svyravimai
Žemiau vidurkio
Naujienų apimtis (RCV)
Aukščiau vidurkio
Finansinės naujienos
Pardavimo ir administravimo išlaidos
Veiklos sąnaudos
Ikimokestinis pelnas
Pardavimai
Pardavimo savikaina
Bendrasis pelnas iš pardavimo
Skolų palūkanų išlaidos
EBITDA
Veiklos pelnas
$
Apie bendrovę Heron Therapeutics Inc
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.